LY2109761 Chemical Properties

Boiling point:

640.9±55.0 °C(Predicted)

Density 

1.34

storage temp. 

Store at -20°C

solubility 

≥22.1 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH

form 

solid

pka

6.27±0.10(Predicted)

color 

White to yellow

InChI

InChI=1S/C26H27N5O2/c1-2-9-27-22(4-1)26-25(24-5-3-11-31(24)29-26)21-8-10-28-23-18-19(6-7-20(21)23)33-17-14-30-12-15-32-16-13-30/h1-2,4,6-10,18H,3,5,11-17H2

InChIKey

IHLVSLOZUHKNMQ-UHFFFAOYSA-N

SMILES

N1C2C(=CC=C(OCCN3CCOCC3)C=2)C(C2C(C3=NC=CC=C3)=NN3CCCC3=2)=CC=1

Safety Information

HS Code 

29349990

LY2109761 Usage And Synthesis

Description

LY2109761 is a novel selective TGF-β receptor type I/II (TβRI/II) dual inhibitor with Ki of 38 nM and 300 nM in a cell-free assay, respectively; shown to negatively affect the phosphorylation of Smad2.

In vitro

LY2109761 treatment induces a dose-dependent low-anchorage growth inhibition of L3.6pl/GLT cells, leading to ~33% or 73% inhibition at 2 μM and 20 μM, respectively, which can be strongly enhanced when combined with gemcitabine in combination index value of 0.36581. Blocking TβRI/II kinase activity with LY2109761 (5 μM) completely suppresses both the basal and TGF-β1-stimulated migration and invasion of L3.6pl/GLT cells, significantly enhances the detachment-induced apoptosis by 26% at 8 hours treatment, and completely suppresses TGF-β–induced Smad2 phosphorylation. LY2109761 treatment at 1 nM is sufficient to significantly block the migration and invasion but not adhesion of hepatocellular carcinoma cells by increasing E-cadherin expression. LY2109761 pretreatment enhances radiosensitivity of glioblastoma cells via TGF-β signaling blockage. LY2109761 (10 μM) reduces the self-renewal and proliferation of GBM-derived cancer stem–like cells (CSLC), which can be significantly enhanced when combined with radiation.

In vivo

Administration of LY2109761 (50 mg/kg) alone or in combination with gemcitabine (25 mg/kg) significantly reduces the tumor volume by ~70% and ~90%, respectively, prolongs the survival with the median survival duration of 45.0 days and 77.5 days, respectively, and reduces spontaneous abdominal metastases in the L3.6pl/GLT Xenograft mice model. In consistent with the in vitro effect, administration of LY2109761 alone or in combination with radiation, markedly inhibits tumor growth in the orthotopical CSLC glioblastoma model by 43.4% and 76.3%, respectively, decreases tumor invasion and tumor microvessel density, and significantly enhances radiation-induced tumor growth delay in the U87MG xenograft mice model.

Description

LY2157299 is a small molecule inhibitor of the TGF-β receptor type 1/type II kinases (IC₅₀ = 69 nM). It has been used to study the role of TGF-β signaling in tumor cell migration and metastasis in pancreatic tumor cell lines where 5 μM of the compound completely disrupts Smad-2 phosphorylation, an immediate downstream target of the kinase activity. It can also suppress radiation-induced inflammatory cytokine signaling and proangiogenic genes, including ID1, in human primary fibrobalsts.

Uses

LY 2109761 is a novel transforming growth factor beta receptor type I and type II dual inhibitor that is potentially used to treat and suppress pancreatic cancer.

Synthesis

The general procedure for the synthesis of 4-(2-((4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl)oxy)ethyl)morpholine from morpholine and the compound (CAS: 700874-75-5) is as follows: 2-[4-(2-pyridin-2-yl-5,6-dihydro-4H- pyrrolo[1,2-b]pyrazol-3-yl)-quinolin-7-yloxy]-ethyl (87 mg, 0.19 mmol) was mixed with morpholine (1 mL) and the reaction was heated at 50 °C for 4 hours. Upon completion of the reaction, excess morpholine was removed by vacuum distillation. Subsequently, the product was separated by extraction using a solvent mixture of isopropanol and chloroform (1:3, v/v). The organic layer was washed with aqueous sodium chloride and dried with anhydrous sodium sulfate. Finally, the title compound (83 mg, 100% yield) was obtained in light yellow solid form by vacuum concentration. Mass spectrometry analysis showed MS ES+ m/e 442.0 ([M+1]+).

in vivo

References

[1]melisi d, ishiyama s, sclabas gm et al. ly2109761, a novel transforming growth factor beta receptor type i and type ii dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. mol cancer ther 2008; 7: 829-840.
[2]li hy, mcmillen wt, heap cr et al. optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type i receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type i inhibitor as antitumor agent. j med chem 2008; 51: 2302-2306.
[3]xu y, tabe y, jin l et al. tgf-beta receptor kinase inhibitor ly2109761 reverses the anti-apoptotic effects of tgf-beta1 in myelo-monocytic leukaemic cells co-cultured with stromal cells. br j haematol 2008; 142: 192-201.
[4]zhang m, kleber s, rohrich m et al. blockade of tgf-beta signaling by the tgfbetar-i kinase inhibitor ly2109761 enhances radiation response and prolongs survival in glioblastoma. cancer res 2011; 71: 7155-7167.
[5]flechsig p, dadrich m, bickelhaupt s et al. ly2109761 attenuates radiation-induced pulmonary murine fibrosis via reversal of tgf-beta and bmp-associated proinflammatory and proangiogenic signals. clin cancer res 2012; 18: 3616-3627.

LY2109761(700874-71-1)Related Product Information

• LY 294002 Hydrochloride
• 1-[5-ETHYL-2-HYDROXY-4-[[6-METHYL-6-(1H-TETRAZOL-5-YL)HEPTYL]OXY]PHENYL]ETHANONE
• LY-404039
• LY3143921
• LY 2606368
• LY 379268
• LY-2940094
• xav-939
• SB 431542
• GW788388
• SB525334
• PLX4032
• LY 2157299